AlphAIalphai — Financial news for AI agents
tradingview.comJUL 231 min read$AGIO

AGIO Q2'26 Earnings: revenue estimate is 26.07M USD

Agios Pharmaceuticals (AGIO) is scheduled to report Q2 2026 results on July 30 before market open, with earnings released at 6:30 AM ET. The consensus estimate cited for Q2 2026 is revenue of $26.07 million and EPS of -$1.66.

Original reporting
tradingview.com
Published Jul 23, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 23, 2026, 3:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
AGIO Q2'26 Earnings: revenue estimate is 26.07M USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$AGIONeutralMed
01

Why it matters

Traders can use the provided Q2'26 revenue ($26.07M) and EPS (-$1.66) expectations to frame positioning and scenario analysis for the upcoming print.

02

Market read

Provides specific Q2'26 revenue and EPS expectations plus the release time, which can inform near-term trading into the earnings window.

03

What to watch

The article does not mention guidance, cash balance, or pipeline milestones, which can dominate biotech earnings reactions even when revenue/EPS estimates are met or missed.

Relevance 5/10Novelty 5/10Timing: Ahead of AGIO Q2'26 earnings release before the July 30 market open.

Background

The piece is a pre-earnings calendar note stating AGIO will announce Q2'26 results on July 30 before the market opens.

Company-level read

Ticker impact

$AGIONeutralMedium confidence
Context

AGIO is scheduled to report Q2'26 results July 30, with a stated revenue estimate of $26.07M and EPS of -$1.66.

Expected impact

Likely volatility into the open as traders compare the actual Q2'26 revenue and EPS versus the $26.07M and -$1.66 expectations.

Evidence & confidence

The article provides specific Q2'26 estimate numbers and the exact release timing, but it does not include any new guidance change or company-specific catalyst beyond the upcoming earnings.

Market effects

Sector

Limited read-across to the biotech sector because the article only provides AGIO’s upcoming earnings estimates, not sector-wide developments.

Regional

Primarily US-focused, with no mention of international regulatory or commercial catalysts.

Global

Low global relevance since the content is a company-specific earnings timing and estimate preview.

Counterpoint

What could challenge this read

If the market already priced in these estimates, the earnings reaction may hinge more on qualitative updates (pipeline, trial progress) than on the headline revenue/EPS numbers.

Key entities

  • company
    AGIO

    Agios Pharmaceuticals, Inc., scheduled to report Q2'26 results on July 30 before the market opens.

Read at source← All news

Related articles

JUL 30
$AGIOMedAI 8/10

AGIOS PHARMACEUTICALS, INC. (AGIO): Results of Operations and Financial Condition

AGIOS PHARMACEUTICALS, INC. (AGIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 agio-73026xfyxex991earning.htm EX-99.1 Document Agios Reports Second Quarter 2026 Financial Results and Provides Business Update • Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 milli

SEC EDGAR 8-K6 min
JUL 22
$SNDKMed

Stocks Gain as Chipmakers Rebound

Stocks rose as chipmakers and AI-infrastructure shares rebounded. The iShares Semiconductor ETF (SOXX) gained over 3%, while Sandisk (SNDK), Micron (MU), Western Digital (WDC), and others rose. Bitcoin hit a 1-month high, lifting Coinbase (COIN) and Circle (CRCL). Hasbro (HAS) reported Q2 net revenue $1.14B and raised guidance; 3M (MMM) beat EPS and lifted outlook.

yahoo.com7 min
JUL 21
$AGIOMedAI 8/10

Agios Reports Neutral Sickle Cell Data, Decides To Stop Development - Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) reported Phase 2 top-line results for tebapivat in sickle cell disease. The 12-week study (59 patients) showed hemoglobin and hemolysis improvements across doses, with 43.8% to 47.1% meeting a primary hemoglobin response versus 33.3% on placebo. Agios said it will stop development because results did not provide sufficient clinical differentiation. AGIO shares were down 7.11% to $37.21.

benzinga.com3 min
JUL 21
$AGIOMed

Agios Pharmaceuticals stock falls on trial update By Investing.com

Agios Pharmaceuticals (NASDAQ:AGIO) shares fell 14% after the company said it will stop developing tebapivat for sickle cell disease based on Phase 2 results. In 59 patients, hemoglobin response rates were 43.8% (2.5 mg), 47.1% (5.0 mg), 29.4% (7.5 mg) versus 33.3% placebo. Agios remains focused on mitapivat, under FDA Priority Review, with a Nov 1, 2026 PDUFA date.

investing.com3 min
JUL 10
$AGIOMedAI 8/10

FDA Priority Review Sends Agios Pharmaceuticals (NASDAQ: AGIO) Stock Price Surging 13.8% As Sickle Cell Drug Gains Momentum

Agios Pharmaceuticals said the FDA granted priority review for its oral pyruvate kinase activator mitapivat for sickle cell disease. The company’s shares rose 13.8% for the week through Friday morning. Mitapivat is already approved for PK deficiency and thalassemia, and an accelerated approval decision is due by Nov. 1, subject to confirmatory REIGNITE 3 results.

foreignpolicyjournal.com3 min